A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.
about
CD40 in coronary artery disease: a matter of macrophages?Immune checkpoint inhibitors: therapeutic advances in melanomaTrial Watch: Immunomodulatory monoclonal antibodies for oncological indicationsImproving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer VaccinationCurrent Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.Immune based therapy for melanomaEnhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.Regulation of atherosclerotic plaque inflammation.Targeting the adaptive immune system: new strategies in the treatment of atherosclerosis.Immuno-regulatory antibodies for the treatment of cancer.Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies.Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering.Expression of CD40 is a positive prognostic factor of diffuse large B-cell lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).Cytokine release syndrome.
P2860
Q26752784-C0E928FE-F0A3-48A9-AE3D-4224D5ADF464Q26775591-5256F2A9-6D07-4406-9755-FDEF11F68098Q26996518-16DC61FA-A4CC-4FE2-86B9-20DD5AAC42F8Q28068378-17D58753-0806-46F0-BBA1-7A969A5BAF1BQ36484383-701966C2-1661-43A3-A38E-A5FA233D2EC6Q36876757-63CA043A-9DE4-4997-BD3E-5D8CADF05CB4Q37114367-7C6EDEDF-1B44-4B80-AEEB-14097191B53FQ37158481-770619A8-17B1-446F-80B4-C510F0DF78A6Q38396097-981BB989-405C-45E3-8F46-D327C8B7C2B0Q38406177-E49BAB22-4568-4835-90BC-8AEE7E74EDE3Q38424617-41F0D316-8FFE-48E5-BB6A-B69ACB9D659AQ38799409-7335A33B-F7D1-4EC3-AB33-D562D604A8E1Q39279968-65EB2F83-ACC0-4DC4-A92E-59923AED74E7Q41788230-0279A25D-C361-4B36-83CE-097E3A0F927DQ55438228-F08B21E0-13F8-46BC-9958-045C40E117CA
P2860
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A phase II study of dacetuzuma ...... s of patient-specific factors.
@ast
A phase II study of dacetuzuma ...... s of patient-specific factors.
@en
type
label
A phase II study of dacetuzuma ...... s of patient-specific factors.
@ast
A phase II study of dacetuzuma ...... s of patient-specific factors.
@en
prefLabel
A phase II study of dacetuzuma ...... s of patient-specific factors.
@ast
A phase II study of dacetuzuma ...... s of patient-specific factors.
@en
P2093
P2860
P356
P1476
A phase II study of dacetuzuma ...... s of patient-specific factors.
@en
P2093
Andres Forero-Torres
Bruce D Cheson
Henry Kaplan
John Timmerman
Jonathan G Drachman
Nancy C Whiting
Ranjana Advani
Richard R Furman
Stephen M Ansell
P2860
P2888
P356
10.1186/1756-8722-7-44
P577
2014-06-12T00:00:00Z
P5875
P6179
1045991057